

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Emerald Health Therapeutics, Inc. (the "Issuer").

Trading Symbol: EMH

Number of Outstanding Listed Securities: 213,472,095

Date: September 9, 2022

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Issuer Response:

On August 12, 2022 the Issuer announced that it had identified matters which required the Company to make restatements (the "Restatements") in respect of its

interim consolidated financial statements for the three months ended March 31, 2022 and 2021 (the "Restated Q1 Financial Statements") and related management discussion and analysis (the "Restated MD&A") relating to (a) cash and cash equivalents (b) revenue from sale of goods and (c) impairment of assets.

The Restatements were identified during a review conducted by MNP LLP ("MNP"), the Company's auditor, in accordance with the standards established by the Public Company Accounting Oversight Board (United States) ("PCAOB") to satisfy the requirements for inclusion of the Company's previously filed financial statements and management's discussion and analysis into the Skye Bioscience, Inc. ("Skye") proxy statement in Form 14A in connection with the previously announced arrangement involving the Company and Skye.

On August 19, 2022, the Issuer reported that its shareholders voted in favour of all resolutions presented at its annual and special meeting. The resolution to approve the proposed plan of arrangement with Skye was approved by 87.07% of votes cast by shareholders for that resolution. The Arrangement resolution also received majority of the minority approval, excluding interested parties pursuant to applicable law.

Shareholders also re-elected Jim Heppell, Punit Dhillon and Bobby Rai as directors of the Company for the ensuing year; and approved MNP LLP as auditor of the Company for the ensuing year.

On August 26, 2022, the Issuer reported that on August 25, 2022, the Supreme Court of British Columbia issued a final order approving the Arrangement with Skye.

Completion of the Arrangement remains subject to approval by the shareholders of Skye, which is scheduled for September 30, 2022. Upon receiving Skye shareholder approval, the transaction is required to close prior to October 15, 2022, subject to Skye obtaining listing approval from the CSE and satisfaction of other customary conditions.

On August 31, 2022, the Issuer reported its financial results for the quarter ended June 30, 2021.

2. Provide a general overview and discussion of the activities of management.

Issuer Response: The Issuer's management continued to focus on business activities related to its transition out of the cannabis business in Canada and has been actively seeking purchasers for its cannabis assets. Management also focused efforts across the enterprise to reduce its cash burn.

Management continued to work diligently to complete the transaction related to the proposed Plan of Arrangement (the "Arrangement"), announced on May 12, 2022, whereby Skye would acquire all the issued and outstanding shares of Emerald in a share-for-share-transaction.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Issuer Response: None noted.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Issuer Response: None noted.

5. Describe any new business relationships entered between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Issuer Response: None noted.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Issuer Response: None noted.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Issuer Response: None noted.

8. Describe the acquisition of new customers or loss of customers.

Issuer Response: Aside from the acquisition or loss of individual medical patient customers as a part of the Issuer's pivot out of the Canadian cannabis industry, the Issuer has no further customer acquisitions or losses to report.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

Issuer Response: None noted.

10. Report on any employee hirings, terminations or lay-offs with details of the anticipated length of lay-offs.

Issuer Response: None noted.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Issuer Response: None noted.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Issuer Response: On June 16, 2020, a Plaintiff filed a Statement of Claim on behalf of a proposed class in the Court of Queen's Bench of Alberta in Alberta, Canada, against several Canadian cannabis manufacturers and/or distributors (the "Defendants"). The Company is named as a Defendant in the proceedings. In the action, it is alleged that the Defendants, including the Company, marketed medicinal and recreational cannabis products with advertised THC or CBD content levels different than those products contained. The action only specifically mentions one product manufactured and sold by the Company – Sync 25, a CBD oil which is alleged to have had at the time of testing an advertised THC level of 1 mg/mL, but an alleged actual THC potency of 0.46 mg/mL. The Plaintiffs claim damages against the Defendants as a group of \$500 million, plus punitive damages of \$5 million, an accounting of revenues, and interest and costs. The Plaintiffs have not yet demanded that the Company defend the action. No certification application has yet been filed.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Issuer Response: None noted.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
N/A	N/A	N/A	N/A

(1) State aggregate proceeds and intended allocation of proceeds.

Issuer Response: None noted.

15. Provide details of any loans to or by Related Persons.

Issuer Response: None noted.

16. Provide details of any changes in directors, officers or committee members.

Issuer Response: None noted.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

Issuer Response: The trends and risks which are likely to impact the Issuer are detailed in the Issuer's most recently filed management's discussion and analysis and annual information form; and in the Issuer's other public filings, all of which are available under the Issuer's SEDAR profile at www.sedar.com, and which are incorporated into this report by reference thereto.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All the information in this Form 7 Monthly Progress Report is true.

Dated September 09, 2022

Moe Jiwan

Name of Director or Senior
Officer

/s/ Moe Jiwan

Signature

Chief Operating Officer

Official Capacity

Issuer Details Name of Issuer Emerald Health Therapeutics, Inc.	For Month End 22/08/31	Date of Report YY/MM/D 22/09/09
Issuer Address 101-4226 Commerce Circle		
City/Province/Postal Code Victoria, British Columbia V8Z 6N6	Issuer Fax No. (855) 624 3325	Issuer Telephone No. (800) 757-3536
Contact Name Moe Jiwan	Contact COO	Contact Telephone No. (800) 757-3536
Contact Email Address invest@emeraldhealth.ca	Web Site Address www.emeraldhealth.ca	